Graham Capital Management, L.P. Atea Pharmaceuticals, Inc. Transaction History

Graham Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $31,883 - $38,146	11,387 New	11,387 $34,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $32,462 - $51,171	10,113 New	10,113 $37,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $704,817 - $1.13 Million	128,382 Added 594.61%	149,973 $853,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $289,024 - $443,568	-54,226 Reduced 71.52%	21,591 $153,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $233,178 - $389,619	42,396 Added 126.85%	75,817 $547,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $256,339 - $1.49 Million	33,421 New	33,421 $298,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $262M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.